Jim Murray is our Chief Development Operations Officer. He has over 20 years of industry experience and has been involved in the execution of over 40 Phase 1 – Phase 3 clinical studies in oncology, autoimmune and rare disease indications. He oversaw the global registrational studies that resulted in the FDA approvals of Onivyde and Imcivree. Prior to TScan, he has been the Head of Clinical Operations at Merrimack Pharmaceuticals, Rhythm Pharmaceuticals and most recently at Repertoire Immune Medicines, where he was Vice President of Clinical Operations, responsible for the execution of two T-cell therapy programs in oncology. He received his B.S. in Biology from Boston College and he completed an executive management program in biotechnology from Harvard Business School.

Away from TScan, Jim enjoys running and golfing.